Liver Transplant Failure Clinical Trial
Official title:
Early Allograft Failure Simplified Estimation (EASE). A Novel Predictive Model for Estimating Early Allograft Failure in Liver Transplantation: a Multicenter Italian Study With a UK Validation Cohort.
A variety of clinical scores have been developed with the intent to predict early allograft
failure after liver transplantation. With the present study the investigators aim to validate
the recently published L-GrAFT Score on a multicenter cohort from 14 liver transplant centers
in Italy.
Secondly, after identifying coefficients which are peculiar for the Italian transplant
population, the investigators aim to develop a novel, simplified model for the estimation of
early allograft failure (EASE Score).
Thirdly, the investigators plan to validate the EASE Score on a population from two liver
transplant centers in the United Kingdom.
Liver transplantation (LT) is the gold standard treatment for end-stage liver disease. The
broadening of indications has caused a growing gap between patients on the waiting list and
those who receive a transplant with the consequence of patients still dying while awaiting to
be transplanted.
This phenomenon has led the transplant community to expand the donors pool, thus including
organs with a higher risk profile. The so called marginal organs carry a higher risk of
failure especially in the early post-transplant phase. Early allograft failure (EAF) is known
as a poor prognostic factor for patient survival.Treatment of graft failure is based on
re-transplantation (Re-LT).
However, there are no clear-cut clinical/biochemical parameters to base the decision of Re-LT
on. In addition, to which extent EAF is irreversible is not entirely predictable. Such
prediction has been the objective of extensive research and debate as it can guide the
physicians through the decision whether or not re-transplanting a recipient of a failing
graft.
The availability of an easy algorithm to quickly identify the cases who are irreversibly
heading towards graft failure and need re-LT is highly desirable.
Various definitions of EAF have been introduced but they all share the same limitation of
being based on a dichotomous evaluation of biochemical parameters (e.g. AST, INR, bilirubin,
etc. below or above a certain cut-off level).
Recently, a new score has been developed with the aim of overcoming this limitation: the
Liver Graft Assessment Following Transplantation (L-GrAFT). This score not only provides a
tool to diagnose EAF but also assesses the severity and the evolution of EAF using the
kinetics of a set of biochemical parameters. However, L-GrAFT is predictive of EAF at 90
days, is based on 31 biochemical determinations and has not been validated in a multicenter
setting.
With the present study the investigators aim:
1. to evaluate the performance of the L-GrAFT score and its ability to predict graft loss
in the early post-operative phase (i.e. 90 days after LT) in a cohort of patients who
received a primary LT from 2016 to 2017 in one of 14 LT Centers based in Italy,
analyzing their prospectively maintained databases with a minimum follow up of 6 months;
2. to develop a simplified algorithm, derived from the L-GrAFT algorithm, based on the
Italian LT population, reducing the number of determinations allowing an easier data
entry, which is predictive of EAF at 90 (90dEASE Score) and also at 30 days post LT
(30dEASE Score);
3. to validate the EASE scores on a population internal to the Italian database, using
bootstrap methodology;
4. to validate the EASE scores on an external UK liver transplant Cohort. The investigators
are planning to present the results of the study in international congresses and
meetings and after that to produce a manuscript.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04789213 -
Mortality, Morbidity and Risk Factors of Liver Retransplantation
|
||
| Recruiting |
NCT06225206 -
Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients
|
||
| Withdrawn |
NCT03846089 -
Retrograde Reperfusion Versus Antegrade Liver Transplant Reperfusion
|
||
| Active, not recruiting |
NCT03815864 -
Antibodies and Liver Retransplantation
|
||
| Recruiting |
NCT05361044 -
Liver Graft Viability Assessment During Normothermic Regional Perfusion
|
N/A | |
| Recruiting |
NCT05866796 -
Serum GLYcomics to Predict Graft Loss and Mortality After Liver Transplantation
|
||
| Active, not recruiting |
NCT03396016 -
Plasmatic Factor V as a Predictor of Graft Dysfunction After Liver Transplantation
|